Concepedia

D. Solit

DS

Statistics

Publications

5

Citations

239

H-Index

5

Active since

2001

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

Vanderbilt-Ingram Cancer Center

Dana-Farber Cancer Institute

Scripps MD Anderson Cancer Center

Breast Cancer Research Foundation

D. Solit is an author at Memorial Sloan Kettering Cancer Center specializing in oncology, medicine, and molecular oncology.

Publications per year

2001–2017

5

Publications

5

Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001.

Pamela N. Münster, Andrea Basso, D. Solit et al. · PubMed · 2001 · 173 citations

, , +17

Abstract PD2-08: Neratinib + fulvestrant in <i>ERBB2</i>-mutant, HER2–non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): Preliminary analysis from the phase II SUMMIT trial

Daniel Hyman, Sarina A. Piha‐Paul, Cristina Saura et al. · Cancer Research · 2017 · 18 citations

, , +17

Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity - eScholarship

Adam B. Olshen, Ch'ang Mt, Shailendra Asthana et al. · 2016 · 17 citations

, , +16

Phase I trial of KOS-953, a heat shock protein 90 inhibitor, and trastuzumab (T)

Shanu Modi, A. Stopeck, Michael S. Gordon et al. · Journal of Clinical Oncology · 2006 · 16 citations

, , +17

Abstract PD5-05: Neratinib for <i>ERBB2</i> mutant, HER2 non-amplified, metastatic breast cancer: Preliminary analysis from a multicenter, open-label, multi-histology phase II basket trial

DM Hyman, SA Piha-Paul, Jordi Rodón et al. · Cancer Research · 2016 · 15 citations

, , +17

1–5 of 5